Risky Business: Government’s Biomarker Efforts Can Go Where Pharma Won’t
Executive Summary
Government research on biomarkers should venture into areas of risky development where pharmaceutical companies will not, a National Cancer Institute official told the Institute of Medicine's National Cancer Policy Forum March 20